Search clinical trials for: REVITIVE IX

Total 411 results

Imperial College London

Completed

Adjuvant Benefit of NMES to Supervised Exercise in Patients With IC (AdjIC)

Intermittent Claudication | Peripheral Vascular Disease | Lower Limb Arterial Disease

United Kingdom
Imperial College London
Actegy Ltd.

Completed

REVITIVE for the Treatment of Patients With Venous Insufficiency (RVI)

Varicose Veins | Venous Insufficiency | Oedema

United Kingdom
Imperial College London

Terminated

Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia

Peripheral Arterial Disease | Critical Limb Ischaemia

United Kingdom
Imperial College London
Actegy Ltd.

Completed

DESIVI: Dosing of Electrical Stimulation in Venous Insufficiency (DESIVI)

Varicose Veins | Venous Insufficiency | Venous Stasis
Ixchelsis Limited

Completed

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)

Premature Ejaculation

United States
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Severe Hemophilia B

Sweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

RIXUBIS PMS India (RIXUBIS PMS)

Hemophilia B

India
Ixchelsis Limited
HealthCore-NERI; Novotech (Australia) Pty Limited; ICON plc; PHT Corporation

Completed

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)

Premature Ejaculation

United States, Australia
Ixchelsis Limited

Completed

Relative Bioavailability and Food Effect Study of IX-01 Capsules in Healthy Men

Healthy Participants

United Kingdom
Baxalta now part of Shire
Takeda

Completed

RIXUBIS Drug Use-Result Survey (Japan)

Hemophilia B

Japan
Catalyst Biosciences

Completed

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

Hemophilia B

South Africa
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B

Hemophilia B
Ixchelsis Limited

Completed

A Study of Multiple Oral Doses of IX-01 in Healthy Male Subjects

Healthy Volunteers

United Kingdom
Ixchelsis Limited

Completed

A Study of Multiple Oral Doses of IX-01 in Healthy Men

Healthy Participants

United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX

Hemophilia B

France
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (Kids B-LONG)

Hemophilia B

United States, United Kingdom, South Africa, Netherlands, Ireland, Australia
Imperial College London

Completed

NMES for Rehab After Surgery

Vascular Diseases | Surgery

United Kingdom
Convergent Genomics, Inc.

Completed

Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX ) (CGI-EPM-IX)

SARS-CoV-2

United States
Medexus Pharma, Inc.

Terminated

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Hemophilia B

United States, United Kingdom, India
Grifols Biologicals, LLC

Completed

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

Hemophilia B

Bulgaria
Pfizer

Completed

Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B

Hemophilia B

Korea, Republic of
Pfizer

Completed

Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

Hemophilia B

United States, Spain, Croatia, Serbia, Russian Federation, Canada, Hungary, Italy, Romania
National Center for Research Resources (NCRR)
University of North Carolina

Completed

Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency

Hemophilia B | Factor IX Deficiency
Ixchelsis Limited

Completed

Relative Bioavailability Study of IX-01 Caplet Versus Aqueous Dispersion and Food Effect of the Caplet in Healthy Males (IX-0106 RBA)

Healthy

United States
Imperial College Healthcare NHS Trust

Withdrawn

Blood Flow Changes in Femoral-popliteal Bypass Grafts After Neuromuscular Electrical Stimulation (NMES). (HAEMUS)

Peripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Femoral Popliteal Occlusion

United Kingdom
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years

Haemophilia B

Poland, Ukraine
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B

Haemophilia B

United Kingdom
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion...

Recruiting

Insufficient Oxygenation in Septic Patients (INOX-SEPSIS)

Sepsis | Fluid Therapy | Critical Care | Oxygen | Mitochondria

Netherlands
Assiut University

Unknown

Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis

Pancreatitis, Acute

Egypt
Dartmouth-Hitchcock Medical Center

Enrolling by invitation

Portable Measurement of Protoporphyrin IX in the Skin

Photodynamic Therapy | Protoporphyrin IX

United States
Tulane University
Genentech, Inc.

Recruiting

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

Hemophilia A

United States
Baxalta now part of Shire

Completed

IMMUNINE Pre-Treatment Study

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Brazil, Czechia, Russian Federation, Ukraine
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients

Haemophilia B

United Kingdom, Poland
Bio Products Laboratory

Completed

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

Haemophilia B

Poland, Romania, Russian Federation
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Cooperative Study of Factor VIII Inhibitors

Hematologic Diseases | Hemophilia A | Blood Coagulation Disorders | Hemorrhagic Disorders
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.

Haemophilia B

United Kingdom
Baxalta now part of Shire

Completed

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

Hemophilia B

Korea, Republic of
Medexus Pharma, Inc.

Completed

Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Hemophilia B

United States, France, United Kingdom, India, Israel, Italy, Poland
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Hemophilia B

Bulgaria, Israel
Baxalta now part of Shire

Completed

Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients

Hemophilia B

Poland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
CSL Behring

Active, not recruiting

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

Hemophilia B

United States, Belgium, Netherlands, Denmark, Germany, Ireland, Sweden, United Kingdom
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum; Syntonix Pharmaceuticals, Inc.

Completed

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Hemophilia B

United States
CSL Behring

Completed

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

Hemophilia B

Germany, Denmark, Netherlands
CSL Behring

Completed

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Hemophilia B

Spain, Italy, France, Germany, Austria, Israel
Baxalta now part of Shire

Completed

BAX 326 (rFIX) Continuation Study

Hemophilia B

Taiwan, Colombia, Argentina, Brazil, Bulgaria, Chile, Czechia, India, Ireland, Italy, Japan, Poland, Romania, Russian Federation, Sweden, Ukraine, United Kingdom
Baxalta now part of Shire

Completed

BAX 326 Surgery Study in Hemophilia B Patients

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Czechia, Russian Federation, Ukraine, United Kingdom
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
Imperial College London
Actegy Ltd.

Not yet recruiting

Neuromuscular Electrical Stimulation For The Treatment of Diabetic Neuropathy (NMES-DN)

Diabetic Neuropathies | Diabetic Peripheral Neuropathy | Diabetic Polyneuropathy | Diabetic Complication

United Kingdom

Search clinical trials for: REVITIVE IX

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations